Analysts think TVTX stock price could increase by 51%
May 08, 2025, 11:25 AM
-24.26%
What does TVTX do
Travere Therapeutics, based in San Diego, focuses on developing therapies for rare kidney and metabolic diseases, with products like FILSPARI for IgAN and Pegtibatinase for classical homocystinuria. Founded in 2003, the company employs 380 people and also offers Thiola for cystinuria.
17 analysts think TVTX stock price will increase by 51.37%. The current median analyst target is $30.60 compared to a current stock price of $20.21. The lowest analysts target is $22.22 and the highest analyst target is $49.35.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
